Mentions
Extended reach
Total likes
Video views
AI synopsis
Many discussions praised the findings, stating that 'ablation is better' and inquiring about its practical application, showcasing a collective enthusiasm about its potential to change treatment protocols. Phrases like 'congrats to the teams' and 'great paper on VT ablation' indicate a tone of celebration and impact, enhancing the perception of its relevance and importance in the field.
The majority of discussions reflect a strong support for the findings of the publication, with many agreeing on the superiority of ablation over medication.
Participants exhibit high interest as many discussions prompt further inquiry into the study's methodology and outcomes.
While some participants engage deeply by questioning the practical application of the findings, others seem more focused on basic acknowledgment of the research.
Many contributors express belief in the publication's significant implications for treatment methodologies in cardiology.
Survive the Threat of Slow VT by single-point ablation. @topaloglu_prof @AhmetKorkmaz07A @prof_serkan_cay @drfiratozcan @Mkara_EP @ElifhandeMD @ozcanozeke @candmrhn @gozdesenol @SerhatKocadr @DursunAras2 @DrBerruezo #AblateVT #EPeeps SURVIVE-VT trial at https://t.co/BE8joXGl35 https://t.co/B5rr9y8ZLM
Great paper on VT ablation just published. Proud to be part of it, with Dr Hernández-Madrid https://t.co/y2AqkjRO3h https://t.co/lunp5nRX4O
Estudio SURVIVE VT
#Ritmo23 (Pamplona 15Junio23) @secardiologia *** Artículos destacados 2022
1st time presentation LEVEL-AT trial in Spain. Thank you @ritmo_SEC for the invitation #RITMO2023 #Articulosdestacados22 Congrats @AranyoJulia, Dr Arenal & teams for your papers https://t.co/vrxNYCts4S https://t.co/2Kx4kdt4ON https://t.co/LvMkfxAN74 @tolosanaviu @LluisMont2 https://t.co/5OJBhwTAxN https://t.co/O95evc5Oya
PubMed-https://t.co/sFKLk1CcNG Bayesian Analysis of the Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia Trial @HUCA_Asturias #publiHUCA #Cardiology
This week, John Mandrola MD discusses key topics including VT ablation, heart failure care, and three-vessel disease. He highlights findings from the SURVIVE-VT trial, showing that catheter ablation may offer benefits…
This podcast critiques comments on VT ablation while reviewing EHRA presentations. The SURVIVE-VT trial findings suggest catheter ablation shows better outcomes after 24 months compared to antiarrhythmic drugs. Join…
RT @ACH_epteam: Survive the Threat of Slow VT by single-point ablation. @topaloglu_prof @AhmetKorkmaz07A @prof_serkan_cay @drfiratozcan @Mk…
#ProducciónCientífica @hospital_hvn: "Bayesian analysis of the Substrate Ablation vs. Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia…" #DifundeCiencia #HUVNdivulga #HUVNinvestiga https://t.co/syhXFg0LLn https://t.co/MDbUVqP0F6
PubMed-https://t.co/sFKLk1CcNG Bayesian Analysis of the Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia Trial @HUCA_Asturias #publiHUCA #Cardiology
RT @MargaridaPujol: 1st time presentation LEVEL-AT trial in Spain. Thank you @ritmo_SEC for the invitation #RITMO2023 #Articulosdestacados2…
RT @MargaridaPujol: 1st time presentation LEVEL-AT trial in Spain. Thank you @ritmo_SEC for the invitation #RITMO2023 #Articulosdestacados2…
1st time presentation LEVEL-AT trial in Spain. Thank you @ritmo_SEC for the invitation #RITMO2023 #Articulosdestacados22 Congrats @AranyoJulia, Dr Arenal & teams for your papers https://t.co/vrxNYCts4S https://t.co/2Kx4kdt4ON https://t.co/LvMkfxAN74 @tolosanaviu @LluisMont2 https://t.co/5OJBhwTAxN https://t.co/O95evc5Oya
RT @MargaridaPujol: #Ritmo23 (Pamplona 15Junio23) @secardiologia *** Artículos destacados 2022
RT @MargaridaPujol: #Ritmo23 (Pamplona 15Junio23) @secardiologia *** Artículos destacados 2022
RT @MargaridaPujol: #Ritmo23 (Pamplona 15Junio23) @secardiologia *** Artículos destacados 2022
RT @MargaridaPujol: #Ritmo23 (Pamplona 15Junio23) @secardiologia *** Artículos destacados 2022
#Ritmo23 (Pamplona 15Junio23) @secardiologia *** Artículos destacados 2022
RT @ACH_epteam: Survive the Threat of Slow VT by single-point ablation. @topaloglu_prof @AhmetKorkmaz07A @prof_serkan_cay @drfiratozcan @Mk…
RT @ACH_epteam: Survive the Threat of Slow VT by single-point ablation. @topaloglu_prof @AhmetKorkmaz07A @prof_serkan_cay @drfiratozcan @Mk…
RT @ACH_epteam: Survive the Threat of Slow VT by single-point ablation. @topaloglu_prof @AhmetKorkmaz07A @prof_serkan_cay @drfiratozcan @Mk…
RT @ACH_epteam: Survive the Threat of Slow VT by single-point ablation. @topaloglu_prof @AhmetKorkmaz07A @prof_serkan_cay @drfiratozcan @Mk…
RT @ACH_epteam: Survive the Threat of Slow VT by single-point ablation. @topaloglu_prof @AhmetKorkmaz07A @prof_serkan_cay @drfiratozcan @Mk…
RT @ACH_epteam: Survive the Threat of Slow VT by single-point ablation. @topaloglu_prof @AhmetKorkmaz07A @prof_serkan_cay @drfiratozcan @Mk…
RT @ACH_epteam: Survive the Threat of Slow VT by single-point ablation. @topaloglu_prof @AhmetKorkmaz07A @prof_serkan_cay @drfiratozcan @Mk…
RT @ACH_epteam: Survive the Threat of Slow VT by single-point ablation. @topaloglu_prof @AhmetKorkmaz07A @prof_serkan_cay @drfiratozcan @Mk…
RT @ACH_epteam: Survive the Threat of Slow VT by single-point ablation. @topaloglu_prof @AhmetKorkmaz07A @prof_serkan_cay @drfiratozcan @Mk…
RT @ACH_epteam: Survive the Threat of Slow VT by single-point ablation. @topaloglu_prof @AhmetKorkmaz07A @prof_serkan_cay @drfiratozcan @Mk…
RT @ACH_epteam: Survive the Threat of Slow VT by single-point ablation. @topaloglu_prof @AhmetKorkmaz07A @prof_serkan_cay @drfiratozcan @Mk…
RT @ACH_epteam: Survive the Threat of Slow VT by single-point ablation. @topaloglu_prof @AhmetKorkmaz07A @prof_serkan_cay @drfiratozcan @Mk…
RT @ACH_epteam: Survive the Threat of Slow VT by single-point ablation. @topaloglu_prof @AhmetKorkmaz07A @prof_serkan_cay @drfiratozcan @Mk…
RT @ACH_epteam: Survive the Threat of Slow VT by single-point ablation. @topaloglu_prof @AhmetKorkmaz07A @prof_serkan_cay @drfiratozcan @Mk…
RT @ACH_epteam: Survive the Threat of Slow VT by single-point ablation. @topaloglu_prof @AhmetKorkmaz07A @prof_serkan_cay @drfiratozcan @Mk…
Survive the Threat of Slow VT by single-point ablation. @topaloglu_prof @AhmetKorkmaz07A @prof_serkan_cay @drfiratozcan @Mkara_EP @ElifhandeMD @ozcanozeke @candmrhn @gozdesenol @SerhatKocadr @DursunAras2 @DrBerruezo #AblateVT #EPeeps SURVIVE-VT trial at https://t.co/BE8joXGl35 https://t.co/B5rr9y8ZLM
RT @drdavemd: RCT showing ablation superior to drugs for symptomatic VT, #EPeeps how difficult is this procedure today and is the benefit o…
RCT showing ablation superior to drugs for symptomatic VT, #EPeeps how difficult is this procedure today and is the benefit of the procedure limited to experts doing beaucoup cases? @JACCJournals https://t.co/i543XLfroj
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
New2Trip: Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia https://t.co/Z3nUSugfZY
New2Trip: Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia https://t.co/Z3nUSugfZY
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
New2Trip: Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia https://t.co/Z3nUSugfZY
New2Trip: Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia https://t.co/Z3nUSugfZY
New2Trip: Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia https://t.co/Z3nUSugfZY
New2Trip: Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia https://t.co/Z3nUSugfZY
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @LAHRSonline1: Estudio SURVIVE VT
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @Arritmias_HRC: Great paper on VT ablation just published. Proud to be part of it, with Dr Hernández-Madrid https://t.co/y2AqkjRO3h http…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @LAHRSonline1: Estudio SURVIVE VT
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @LAHRSonline1: Estudio SURVIVE VT
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @LAHRSonline1: Estudio SURVIVE VT
RT @LAHRSonline1: Estudio SURVIVE VT
RT @LAHRSonline1: Estudio SURVIVE VT
RT @LAHRSonline1: Estudio SURVIVE VT
RT @Arritmias_HRC: Great paper on VT ablation just published. Proud to be part of it, with Dr Hernández-Madrid https://t.co/y2AqkjRO3h http…
RT @LAHRSonline1: Estudio SURVIVE VT
RT @Arritmias_HRC: Great paper on VT ablation just published. Proud to be part of it, with Dr Hernández-Madrid https://t.co/y2AqkjRO3h http…
RT @LAHRSonline1: Estudio SURVIVE VT
RT @LAHRSonline1: Estudio SURVIVE VT
RT @LAHRSonline1: Estudio SURVIVE VT
Estudio SURVIVE VT
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
PubMed-https://t.co/nG35WbbHBd Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia @HUCA_Asturias #publiHUCA #Cardiology
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @Arritmias_HRC: Great paper on VT ablation just published. Proud to be part of it, with Dr Hernández-Madrid https://t.co/y2AqkjRO3h http…
RT @Arritmias_HRC: Great paper on VT ablation just published. Proud to be part of it, with Dr Hernández-Madrid https://t.co/y2AqkjRO3h http…
【RCT】ICDショックが適切な虚血性心筋症患者へのカテーテルアブレーションは、抗不整脈薬の投与と比較して、複合転帰（心血管死、適切なICDショック、心不全の悪化または重度の治療関連合併症による予定外入院）を減少させた。 #ペ読 https://t.co/JtBGbmFHb6
From @jaccjournals Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia https://t.co/XTlQqBEzU8
RT @Arritmias_HRC: Great paper on VT ablation just published. Proud to be part of it, with Dr Hernández-Madrid https://t.co/y2AqkjRO3h http…
RT @Arritmias_HRC: Great paper on VT ablation just published. Proud to be part of it, with Dr Hernández-Madrid https://t.co/y2AqkjRO3h http…
Great paper on VT ablation just published. Proud to be part of it, with Dr Hernández-Madrid https://t.co/y2AqkjRO3h https://t.co/lunp5nRX4O
Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia - https://t.co/EXr3vlzwOH
Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia - https://t.co/zy0NxG59kU
Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia https://t.co/HS99UVaGcS
Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia - https://t.co/PJI15uLKBj
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia https://t.co/XCnLEvcndX
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia https://t.co/78onvX7xDg
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @Susumu_Manabe: ICDが装着された虚血性心筋症患者では、抗不整脈薬よりカテーテルアブレーションの方が有害事象（心血管死、ICDショック、予定しない入院、心不全悪化、重篤な治療有害事象）を減らす．無作為化比較試験SURVIVE-IT試験の結果 From @j…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @joselmerino: Today published in JACC our multicentre trial SURVIVE-VT: Ablation is better (composite of HF hospitalizations, CV mortali…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…
RT @DrBerruezo: The SURVIVE-VT Trial is published in JACC. Substrate VT ablation is superior to AADs as first line therapy!! Substrate Abl…